Publications

Listed here are selected publications, recent publications and theses.
Selected publications

Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer

Kudling TV, Clubb JHA, Pakola S, Quixabeira DCA, Lähdeniemi IAK, Heiniö C, Arias V, Havunen R, Cervera-Carrascon V, Santos JM, Sutinen E, Räsänen J, Borenius K, Mäyränpää MI, Aaltonen E, Sorsa S, Hemminki O, Kanerva A, Verschuren EW, Ilonen I, Hemminki A. Oncoimmunology. 2023 Aug 2;12(1):2241710. doi: 10.1080/2162402X.2023.2241710. PMID: 37546696

PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer.

Talwelkar SS, Mäyränpää MI, Schüler J, Linnavirta N, Hemmes A, Adinolfi S, Kankainen M, Sommergruber W, Levonen AL, Räsänen J, Knuuttila A, Verschuren EW, Wennerberg K. Mol Oncol. 2022 Nov 24. doi: 10.1002/1878-0261.13342. Online ahead of print.PMID: 36423211 Free article.

Development of an adenosquamous carcinoma histopathology - selective lung metastasis model.

Lähdeniemi IAK, Devlin JR, Nagaraj AS, Talwelkar SS, Bao J, Linnavirta N, Şeref Vujaklija C, Kiss EA, Hemmes A, Verschuren EW. Biol Open. 2022 Dec 15;11(12):bio059623. doi: 10.1242/bio.059623. Epub 2022 Dec 13.PMID: 36355420 Free PMC article.

Protocol to utilize fresh uncultured human lung tumor cells for personalized functional diagnostics.

Talwelkar SS, Lähdeniemi IAK, Mäyränpää MI, Hemmes A, Linnavirta N, Räsänen J, Knuuttila A, Wennerberg K, Verschuren EW. STAR Protoc. 2022 Dec 16;3(4):101720. doi: 10.1016/j.xpro.2022.101720. Epub 2022 Sep 27.PMID: 36170112 

Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.

Gao Y, Päivinen P, Tripathi S, Domènech-Moreno E, Wong IPL, Vaahtomeri K, Nagaraj AS, Talwelkar SS, Foretz M, Verschuren EW, Viollet B, Yan Y, Mäkelä TP.Clin Cancer Res. 2022 Jan 1;28(1):227-237. doi: 10.1158/1078-0432.CCR-21-2049. Epub 2021 Oct 19.PMID: 34667030 

Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments.

Sarang S. Talwelkar, Mikko I. Mäyränpää, Lars Søraas, Swapnil Potdar, Jie Bao, Annabrita Hemmes, Nora Linnavirta, Jon Lømo, Jari Räsänen, Aija Knuuttila, Krister Wennerberg, Emmy W. Verschuren, Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments, Cell Reports Medicine, Volume 2, Issue 8, 2021, [100373], doi: 10.1016/j.xcrm.2021.100373

SOX9 has distinct roles in the formation and progression of different non-small cell lung cancer histotypes.

Bao, J., Närhi, K., Teodosio, A., Hemmes, A., Linnavirta, N. M., Mäyränpää, M., Salmenkivi, K., Le Quesne, J., & Verschuren, E. W. (2021). SOX9 has distinct roles in the formation and progression of different non-small cell lung cancer histotypes. Journal of Pathology, [105276]. doi: 10.1002/path.5733

Spa-RQ: an Image Analysis Tool to Visualise and Quantify Spatial Phenotypes Applied to Non-Small Cell Lung Cancer.

Bao, J., Walliander, M., Kovacs, F., Nagaraj, A. S., Hemmes, A., Sarhadi, V. K., ... Verschuren, E. W. (2019). Spa-RQ: an Image Analysis Tool to Visualise and Quantify Spatial Phenotypes Applied to Non-Small Cell Lung Cancer. Scientific Reports9, [17613]. doi: 10.1038/s41598-019-54038-9.

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras Mutant Lung Cancers.

Talwelkar, S. S., Nagaraj, A. S., Devlin, J. R., Hemmes, A., Potdar, S., Kiss, E. A., ... Verschuren, E. (2019). Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras Mutant Lung Cancers. Molecular Cancer Therapeutics18(10), 1863-1874. doi: 10.1158/1535-7163.MCT-18-0573.

Establishment and Analysis of Tumor Slice Explants As a Prerequisite for Diagnostic Testing.

Nagaraj, A. S., Bao, J., Hemmes, A., Machado, M., Närhi, K., & Verschuren, E. W. (2018). Establishment and Analysis of Tumor Slice Explants As a Prerequisite for Diagnostic Testing. Journal of Visualized Experiments141, [e58569]. doi: 10.3791/58569.

Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours.

Närhi, K., Nagaraj, A. S., Parri, E., Turkki, R., van Duijn, P. W., Hemmes, A., ... Verschuren, E. W. (2018). Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours. Journal of Pathology245(1), 101-113. doi: 10.1002/path.5059.

Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.

Nagaraj, A. S., Lahtela, J., Hemmes, A., Pellinen, T., Blom, S., Devlin, J. R., ... Verschuren, E. W. (2017). Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1. Cell Reports18(3), 673-684. doi: 10.1016/j.celrep.2016.12.059.

Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices.

Davies, E., Dong, M., Gutekunst, M., Narhi, K., van Zoggel, H. J. A. A., Blom, S., ... Hickman, J. A. (2015). Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices. Scientific Reports5, [17187]. doi: 10.1038/srep17187.

The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis.

Jenni Lahtela, Barun Pradhan, Katja Närhi, Annabrita Hemmes, Merja Särkioja, Panu E. Kovanen, Arthur Brown, Emmy W. Verschuren. The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis. Disease Models & Mechanisms 2015 8: 393-401; doi: 10.1242/dmm.019257.

Recent publications
Preprints
Book chapter

Closing chapter in "Rethinking Cancer: A new Paradigm for the Postgenomics Era"

Edited by Bernhard Strauss, Marta Bertolaso, Ingemar Ernberg, and Mina J. Bissell

The MIT Press, Cambridge Massachusetts & London, England

Emmy W. Verschuren "Niche Reconstruction to Revert or Transcend the Cancer State”